Best Oligonucleotide / ASO CDMOs in Asia

← All Oligo/ASO CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
9
CDMOs tracked
5
Fully scored
1
With FDA records
2
FDA inspections
5
EMA/MHRA GMP certs

For Asia-manufactured oligonucleotide / aso programs, Ajinomoto Bio-Pharma Services, ST Pharm, and Sumitomo Chemical Advanced Medical lead CDMO Signal's ranking of oligonucleotide / aso CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 20 scored oligonucleotide / aso CDMOs to 5 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.

Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 0 NAI (no action), 1 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (2), Czechia (2), Germany (1), Ireland (1), UNITED STATES (1).

Last updated 2026-07-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
 85.6 100.0 0 insp · 1 GMP — 0 programs
2
SP
ST Pharm
Seoul, South Korea
 72.8 88.1 2 insp · 4 GMP — 0 programs
3
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
 63.0 — — — 0 programs
4
AU
Aurigene Pharmaceutical Services
Hyderabad, India
 63.0 — — — 0 programs
5
RR
RiboBio
Guangzhou, CN
 59.0 — — — 0 programs
—
Sai Life Sciences
Hyderabad, India
 Profiled — — — 0 programs
—
Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
Indianapolis, IN
 Profiled — — — 0 programs
—
Asymchem / AsymBio
Morrisville, NC (US HQ); Tianjin, China (primary manufacturing)
 Profiled — — — 0 programs
—
WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)
Shanghai, China
 Profiled — — — 0 programs
How we score CDMOs →

What to evaluate in a Oligonucleotide / ASO CDMO

Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Oligonucleotide / ASO CDMOs — Frequently Asked Questions

Who are the top Oligonucleotide / ASO CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Oligonucleotide / ASO CDMOs include Ajinomoto Bio-Pharma Services, ST Pharm, Sumitomo Chemical Advanced Medical. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Oligonucleotide / ASO CDMOs have FDA inspection records?
CDMO Signal tracks 1 Oligonucleotide / ASO CDMO with FDA inspection records and 5 EMA/MHRA GMP certificates across the group.
What should I look for in an oligonucleotide CDMO?
Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.
What therapeutics do oligonucleotide CDMOs make?
Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.
Related modalities
Plasmid DNA CDMOs mRNA / LNP CDMOs Biologics / mAb CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Adenoviral Gene Editing Exosome Recombinant Proteins ADC